INTERMEDIATE HIGH-DOSE ARA-C (I-HIDAC) - TOXICITY AND REMISSION INDUCTION IN POOR-RISK AML

被引：0
|
作者：
MITROU, PS [1 ]
HOELZER, D [1 ]
GANSER, A [1 ]
BERGMANN, L [1 ]
机构：
[1] JOHANN WOLFGANG GOETHE UNIV,ZENTRUM INNEREN MED,HAMATOL ABT,FRANKFURT,FED REP GER
来源：
BLUT | 1986年 / 53卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：243 / 243
页数：1
相关论文
共 50 条
  • [21] HIGH-DOSE ARA-C RELATED LEUKOENCEPHALOPATHY
    HWANG, TL
    YUNG, WKA
    LEE, YY
    BORIT, A
    FIELDS, WS
    JOURNAL OF NEURO-ONCOLOGY, 1986, 3 (04) : 335 - 339
  • [22] HIGH-DOSE ARA-C THERAPY - A REVIEW
    GASSMANN, W
    SCHMITZ, N
    LOFFLER, H
    ONKOLOGIE, 1985, 8 (01): : 8 - &
  • [23] INTERMEDIATE-DOSE ARA-C AND IDARUBICIN FOLLOWED BY LOW-DOSE ARA-C IS PARTICULARLY EFFECTIVE IN UNMAINTAINED RELAPSED AML
    MUUS, P
    DEWITTE, T
    RAEMAEKERS, J
    BLOOD, 1994, 84 (10) : A146 - A146
  • [24] DAE (DAUNORUBICIN, ARA-C, AND ETOPOSIDE) AND INTERMEDIATE DOSE ARA-C FOR REMISSION INDUCTION AND CONSOLIDATION TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    HWANG, WL
    YOUNG, JH
    GAU, JP
    HU, HT
    TSAI, YT
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (06): : 531 - 534
  • [25] EFFICACY OF HIGH-DOSE (HD) AND INTERMEDIATE-DOSE (ID) ARA-C IN PATIENTS WITH SECONDARY LEUKEMIA (SEC AML), REFRACTORY (REF) AML AND RELAPSING (REL) AML
    JAGER, U
    SCHWARZINGER, I
    NEUMANN, E
    BAILER, H
    NIESSNER, H
    HINTERBERGER, W
    BETTELHEIM, P
    PANZER, S
    POLLAK, C
    PABINGERFASCHING, I
    FISCHER, M
    GEISSLER, K
    VIKYDAL, R
    GOSSINGER, H
    LECHNER, K
    BLUT, 1985, 51 (03): : 211 - 211
  • [26] TREATMENT OF INTRAOCULAR LYMPHOMA WITH HIGH-DOSE ARA-C
    BAUMANN, MA
    RITCH, PS
    HANDE, KR
    WILLIAMS, GA
    TOPPING, TM
    ANDERSON, T
    CANCER, 1986, 57 (07) : 1273 - 1275
  • [27] High Complete Remission (CR) Rates and Reduced Early Mortality with High Dose Ara-c (HiDAC) and Mitoxantrone (MITO) Induction Chemotherapy for Older (age>60) High Risk Patients with Acute Myeloid Leukemia (AML)
    Kamanathan, Muthalagu
    Zhou, Zheng
    Cerny, Jan
    Raffel, Glen D.
    Petrillo-Deluca, Laura
    Walsh, William Vincent
    Bathini, Venu
    Vail, Micheal
    Smethers, Karen
    Woda, Bruce
    Miron, Patricia
    Rosmarin, Alan G.
    Nath, Rajneesh
    BLOOD, 2010, 116 (21) : 1348 - 1348
  • [28] RELATIONSHIP OF [H-3] ARA-C INCORPORATION AND RESPONSE TO THERAPY WITH HIGH-DOSE ARA-C IN AML PATIENTS - A LEUKEMIA INTERGROUP STUDY
    RAZA, A
    GEZER, S
    ANDERSON, J
    LYKINS, J
    BENNETT, J
    BROWMAN, G
    GOLDBERG, J
    LARSON, R
    VOGLER, R
    PREISLER, HD
    EXPERIMENTAL HEMATOLOGY, 1992, 20 (10) : 1194 - 1200
  • [29] BIOCHEMICAL AND PHARMACOLOGICAL BASIS OF HIGH-DOSE ARA-C
    SEEBER, S
    ONKOLOGIE, 1985, 8 (01): : 4 - 7
  • [30] THE ASSOCIATION OF HIGH-DOSE ARA-C AND DEMYELINATING POLYNEUROPATHY
    OPENSHAW, H
    SLATKIN, NE
    HINTON, DR
    ZAIAS, B
    STEIN, AS
    ANNALS OF NEUROLOGY, 1995, 38 (02) : 342 - 342
12345